Drugs and Medicaments: World Trade, Markets and Competitors

Drugs and Medicaments: World Trade, Markets and Competitors

In 2023 world trade of Drugs and Medicaments recorded a value of 862.6 Bn $, with a negative trend (-2.6%) compared to 2022.

Worldwide flows of Drugs and Medicaments recorded a Compound Annual Growth Rate (CAGR) in $ of +23.8% in the period 2001-2008 and of +5.6% in the period 2009-2023.

In the 2024-2027 scenario, world trade of Drugs and Medicaments is expected to have a CAGR of +7.8% in $.

The report includes an analysis of 20 major importing countries of Drugs and Medicaments, as regards:

• import size and evolution both in values and volumes over the period 1995-2023
• import segmentation by price-ranges and evolution 2023 vs 2013
• import shares and price positioning by partner countries (competitors) in 2018-2023
• forecast of import values and shares by competitors up to 2027.

The report also includes an analysis of 20 major exporting countries of Drugs and Medicaments, as regards:

• export size and evolution both in values and volumes over the period 1995-2023
• export segmentation by price-ranges and evolution 2023 vs 2013
• export shares and price positioning by destination countries (markets) in 2018-2023
• forecast of export values and shares by markets up to 2027.

Information contained in this report is derived from the Ulisse Database , that was developed from the UN (Comtrade), Eurostat (db Comext) and US Census Bureau (db UsaTrade) databases.

The Ulisse Database basic unit is the Annual Flow of World Trade between two partner countries for Drugs and Medicaments.

Forecasts contained in this report have been developed by StudiaBo from the Ulisse Database and the World Economic Outlook (WEO) database, periodically released by the International Monetary Fund.

Forecasts are the output of an integrated econometric model of demand and competitiveness, that is based on expected macroeconomic trends and capacity of countries to compete in international markets. They provide a robust estimate of the scenario of Drugs and Medicaments’ world trade.